Examining the Controversial Role of Pharmacy Benefit Managers in U.S. Healthcare

TL/DR –

Pharmacy Benefit Managers (PBMs) are companies acting as intermediaries between insurance companies and pharmacies, deciding medication coverages, co-pays, and pharmacy usage for health insurance plans. These companies have come under scrutiny for their role in driving independent pharmacies out of business. Regulatory efforts have increased, including the House passing a provision to eliminate spread pricing (which allows PBMs to charge higher prices for drugs than the cost of obtaining them from pharmacies), and a recent antitrust victory against a PBM by a non-profit organization, while the FTC has filed federal action against the largest PBMs for anticompetitive practices.

The Role and Impact of Pharmacy Benefit Managers in the U.S. Health Care System

The U.S health care system is burdened by the presence of pharmacy benefit managers (PBMs), companies that act as middlemen between pharmacies and insurance companies. These intermediaries decide on patient medication coverage, co-pays, and preferred pharmacies. They also influence reimbursements for pharmacies from insurance companies.

Lawyers and lawmakers across the nation, from Connecticut to Florida, are examining the impact of these PBMs, with Alabama proposing regulations to control their fees and reimbursements.

The attorneys general of 39 states have urged Congress to prohibit PBMs from operating pharmacies, alleging that they manipulate prices and hinder independent pharmacies. In line with this, the House recently passed a bill to eliminate spread pricing.

As per Federal Trade Commission, three companies, CVS Caremark, OptumRx, and Express Scripts, dominate 80% of the pharmaceutical market. This dominance gives PBMs considerable power over pharmacies, compelling them to accept negotiated payments, irrespective of fairness.

Efforts for regulating these middlemen intensified about ten years ago when Arkansas set a precedent for PBM oversight. Nonprofit organizations, including AIDS Healthcare Foundation, have also made legal strides against PBMs, including a significant antitrust victory against Prime Therapeutics.

There have been numerous class action lawsuits against PBMs over the past year. Despite PBMs claiming to lower drug costs, they have been accused of inflating prices, limiting medication access, and enhancing profits for their corporate owners.

While state governments and nonprofits persist in the fight for reform, the ultimate resolution lies in federal action to dismantle the PBM monopoly on prescription drugs.

—
Read More Health & Wellness News ; US News